Dermapharm's Branded Pharmaceuticals Segment Bolsters Growth

Dermapharm Holding SE reported a 1.7% increase in consolidated revenue, reaching EUR 884.4 million for the first nine months of 2026. This growth is attributed to the strong performance of the "Branded pharmaceuticals" segment, which experienced an 8.1% revenue increase, driven by organic growth and contributions from recent acquisitions, Mucos and F. Trenka. Contrarily, the "Parallel import business" saw a decline due to portfolio optimization.

Adjusted EBITDA increased by 5.1% to EUR 248.1 million, with the EBITDA margin improving to 28.0%. The Board of Management reaffirms its positive outlook for 2026, anticipating revenues between EUR 1,182 million and EUR 1,218 million, with adjusted EBITDA expected to range from EUR 331 million to EUR 341 million.

The "Other healthcare products" segment faced a slight revenue decline due to seasonal and regulatory factors. Overall, Dermapharm continues to leverage its robust branded pharmaceuticals segment to maintain its growth trajectory.